Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells
Authors:
- Somnath PandeySPSomnath Pandey
- Rahinatou DjiboRDRahinatou Djibo
- Anaïs DarracqADAnaïs Darracq
- Gennaro CalendoGCGennaro Calendo
- Hanghang ZhangHZHanghang Zhang
- Ryan A. HenryRHRyan A. Henry
- Andrew J. AndrewsAAAndrew J. Andrews
- Stephen B. BaylinSBStephen B. Baylin
- Jozef MadzoJMJozef Madzo
- Rafael NajmanovichRNRafael Najmanovich
- Jean-Pierre J. IssaJIJean-Pierre J. Issa
- Noël J.-M. RaynalNRNoël J.-M. Raynal
Open Access
Abstract
Aberrant transcription in cancer cells involves the silencing of tumor suppressor genes (TSGs) and activation of oncogenes. Transcriptomic changes are associated with epigenomic alterations such as DNA-hypermethylation, histone deacetylation, and chromatin condensation in promoter regions of silenced TSGs. To discover novel drugs that trigger TSG reactivation in cancer cells, we used a GFP-reporter system whose expression is silenced by promoter DNA hypermethylation and histone deacetylation. After screening a natural product drug library, we identified that toyocamycin, an adenosine-analog, induces potent GFP reactivation and loss of clonogenicity in human colon cancer cells. Connectivity-mapping analysis revealed that toyocamycin produces a pharmacological signature mimicking cyclin-dependent kinase (CDK) inhibitors. RNA-sequencing revealed that the toyocamycin transcriptomic signature resembles that of a specific CDK9 inhibitor (HH1). Specific inhibition of RNA Pol II phosphorylation level and kinase assays confirmed that toyocamycin specifically inhibits CDK9 (IC50 = 79 nM) with a greater efficacy than other CDKs (IC50 values between 0.67 and 15 µM). Molecular docking showed that toyocamycin efficiently binds the CDK9 catalytic site in a conformation that differs from other CDKs, explained by the binding contribution of specific amino acids within the catalytic pocket and protein backbone. Altogether, we demonstrated that toyocamycin exhibits specific CDK9 inhibition in cancer cells, highlighting its potential for cancer chemotherapy.Keywords
Funding Information
- National Cancer Institute (R01 CA158112, P50 CA100632, P50 CA254897)
- National Cancer Institute (R01 CA158112, P50 CA100632, P50 CA254897)
- National Cancer Institute (R01 CA158112, P50 CA100632, P50 CA254897)
This publication has 60 references indexed in Scilit:
- Differences in Specificity and Selectivity Between CBP and p300 Acetylation of Histone H3 and H3/H4Biochemistry, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicingBlood Cancer Journal, 2012
- Interaction of Rio1 Kinase with Toyocamycin Reveals a Conformational Switch That Controls Oligomeric State and Catalytic ActivityPLOS ONE, 2012
- DNA Methylation Does Not Stably Lock Gene Expression but Instead Serves as a Molecular Mark for Gene Silencing MemoryCancer Research, 2012
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung CancerCancer Discovery, 2011
- A decade of exploring the cancer epigenome — biological and translational implicationsNature Reviews Cancer, 2011
- Epigenetic modifications as therapeutic targetsNature Biotechnology, 2010
- Chromatin Remodeling Is Required for Gene Reactivation after Decitabine-Mediated DNA HypomethylationCancer Research, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009